<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01492127</url>
  </required_header>
  <id_info>
    <org_study_id>UF 8671</org_study_id>
    <nct_id>NCT01492127</nct_id>
  </id_info>
  <brief_title>Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment</brief_title>
  <official_title>Evolution of Plasma Proteasome Levels Following Curative Treatment of Hepatocellular Carcinoma in Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the usefulness of plasma proteasome levels as a tumor marker of&#xD;
      hepatocellular carcinoma (HCC) by studying their variation following curative treatment of&#xD;
      HCC. The hypothesis of the study is that plasma proteasome levels will decrease following&#xD;
      curative treatment, and that proteasome levels could be used as a marker to detect early&#xD;
      recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HCC occurs in the vast majority of cases in the context of cirrhosis. Cirrhosis is considered&#xD;
      a pre-cancerous state, which justifies systematic screening for HCC. Screening currently&#xD;
      relies on measurement of alpha-foetoprotein (AFP) levels and ultrasound scans every 4 to 6&#xD;
      months. However, AFP has poor sensitivity as a marker for HCC. We have recently shown that&#xD;
      plasma proteasome levels have a higher sensitivity than HCC for detecting HCC in cirrhotic&#xD;
      patients, particularly when the tumors are small and can still benefit from curative&#xD;
      treatment. The hypothesis of the study is that plasma proteasome levels will decrease&#xD;
      following curative treatment, and that proteasome levels could be used as a marker to detect&#xD;
      early recurrence. The goal of this study is to determine whether plasma proteasome levels in&#xD;
      cirrhotic patients with HCC decrease following curative treatment (radiofrequency, surgical&#xD;
      resection, liver transplantation). Plasma proteasome levels will be measured before treatment&#xD;
      and 3 months after treatment, then subsequently at 3 month intervals over one year following&#xD;
      treatment. The variation of proteasome levels will be compared to AFP levels. The sensitivity&#xD;
      of proteasome as a marker to detect tumor recurrence will be evaluated, and compared to AFP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of plasma proteasome</measure>
    <time_frame>3 months afterwards</time_frame>
    <description>Variation of plasma proteasome levels before curative treatment of HCC and 3 months afterwards</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of plasma proteasome</measure>
    <time_frame>6, 9 and 12 months</time_frame>
    <description>Variation of plasma proteasome levels 6, 9 and 12 months following curative treatment for HCC, comparison with AFP levels and results from imaging studies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Blood test</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Blood test :carcinoma in cirrhotic patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Blood test</description>
    <arm_group_label>Blood test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cirrhotic patients with hepatocellular carcinoma proven by histological examination of&#xD;
             a biopsy specimen, eligible for curative treatment (radiofrequency, surgical&#xD;
             resection, liver transplantation)&#xD;
&#xD;
          -  Patient able to give informed consent&#xD;
&#xD;
          -  Patient with Social Security coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary liver tumors&#xD;
&#xD;
          -  Non hepatocellular carcinoma primary liver tumor&#xD;
&#xD;
          -  Hepatocellular carcinoma without cirrhosis&#xD;
&#xD;
          -  Patients with hepatocellular carcinoma and cirrhosis not eligible for curative&#xD;
             treatment&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Adults under guardianship or curatorship&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Funakoshi</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Henry L, Lavabre-Bertrand T, Vercambre L, Ramos J, Carillo S, Guiraud I, Pouderoux P, Bismuth M, Valats JC, Demattei C, Duny Y, Chaze I, Funakoshi N, Bureau JP, Daur√®s JP, Blanc P. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. Gut. 2009 Jun;58(6):833-8. doi: 10.1136/gut.2008.157016. Epub 2009 Feb 6.</citation>
    <PMID>19201777</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2011</study_first_posted>
  <last_update_submitted>April 22, 2015</last_update_submitted>
  <last_update_submitted_qc>April 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>proteasome</keyword>
  <keyword>alpha-fetoprotein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

